Christopher Garabedian has shown a strong financial commitment to Sarepta Therapeutics. His insider trading activity reflects significant stock holdings with values fluctuating dramatically. For instance, in December 2019, his holdings peaked at approximately $48.54 million. However, fluctuations occurred as values...
Christopher Garabedian has shown a strong financial commitment to Sarepta Therapeutics. His insider trading activity reflects significant stock holdings with values fluctuating dramatically. For instance, in December 2019, his holdings peaked at approximately $48.54 million. However, fluctuations occurred as values dipped to around $31.95 million in September 2019. In 2020, the value of his holdings saw considerable growth, hitting a high of $66.84 million by December. Over the years, his confidence in Sarepta has been apparent in the increasing value of his holdings, which directly ties to the company's drug development successes and FDA approvals. This trend illustrates his alignment with the company's performance, showcasing his commitment to its long-term vision and his stake in its accomplishments.